# US 2003/0083236 A1 · Myelopeptides and their therapeutic use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083236 A1
- Document ID: US20030083236A1
- Status: Published application
- Kind: A1
- Application number: 10/277,622
- Filed: 2002-10-22
- Published: 2003-05-01
- Earliest claimed: 1997-01-07
- Inventors: Rem V. Petrov; Augusta A. Mikhailova; Larissa A. Fonina; Sergei A. Guriyanov
- Web page: https://patentgrep.com/patent/US20030083236A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- C07K 5/1019: {with the first amino acid being basic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention pertains to peptides comprising 4 to 10 amino acids including X1-Pro, Pro-X2 or X1-Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu, Asn and Gln, and the other amino acids are independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Pro, Phe, Tyr, Trp, Cys, Met, Ser and Thr. Such peptides, including LVCYPQ, FRPRIMTP, VVYPD and VDPP, are obtainable from porcine bone marrow cell culture, and have immunostimulating and anti-viral properties.

## Claims

### Claim 1

A peptide comprising 4 to 10 amino acids including X1-Pro, Pro-X2 or X1-Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu, Asn and Gln, and the other amino acids are independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Pro, Phe, Tyr, Trp, Cys, Met, Ser and Thr.

### Claim 2 (depends on 1)

The peptide according to claim 1, which comprises predominantly other amino acids as defined in claim 1.

### Claim 3 (depends on 1)

The peptide according to claim 1, wherein the N-terminal comprises 1, 2, 3 or 4 amino acids independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Phe, Tyr, Trp, Cys and Met.

### Claim 4 (depends on 1)

The peptide according to claim 1, including Pro-X2.

### Claim 5 (depends on 1)

The peptide according to claim 1, wherein X2 is a terminal amino acid.

### Claim 6 (depends on 1)

The peptide according to claim 1, including X1-Pro.

### Claim 7 (depends on 6)

The peptide according to claim 6, including Z-X1-Pro, wherein Z is terminal and one of the other amino acids.

### Claim 8 (depends on 1)

The peptide according to claim 1, which is or comprises LVCYPQ (SEQ ID NO. 3).

### Claim 9 (depends on 1)

The peptide according to claim 1, which is or comprises FRPRIMTP (SEQ ID NO. 4).

### Claim 10 (depends on 1)

The peptide according to claim 1, which is or comprises VVYPD (SEQ ID NO. 5).

### Claim 11 (depends on 1)

The peptide according to claim 1, which is or comprises VDPP (SEQ ID NO. 6).

### Claim 12 (depends on 1)

The peptide according to claim 1, free from other components of bone marrow.

### Claim 13 (depends on 1)

The peptide according to claim 1, in a pharmaceutically acceptable carrier or diluent.

### Claim 14 (depends on 2)

The peptide according to claim 2, wherein the N-terminal comprises 1, 2, 3 or 4 amino acids independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Phe, Tyr, Trp, Cys and Met.

### Claim 15 (depends on 1)

A method for the treatment or prophylaxis of a viral or bacterial infection, or a disease requiring immunostimulation, in a patient, said method comprising administering an effective amount of a peptide of claim 1 to the patient.
